{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"144"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Primary feasibility endpoint is the number of individual toxicities and incidence of significant delays","groups":[{"description":"Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\\>21 yrs of age 600mg daily (DIPG); \\<21 yrs of age 350 mg/m2/day)\n\nRibociclib","id":"OG000","title":"RB+ High Grade Glioma"},{"description":"Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (\\>21 yrs of age 600mg daily (DIPG); \\<21 yrs of age 350 mg/m2/day)\n\nRibociclib","id":"OG001","title":"Non-Biopsied Diffuse Instrinsic Pontine Glioma"}],"paramType":"NUMBER","populationDescription":"Number of participants receiving investigational agent.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Number of Adverse Events","type":"PRIMARY","unitOfMeasure":"adverse event"}